Louise C Strong

List of Publications by Year
in descending order

38 papers	2,065 citations	361413 20 h-index	302126 39 g-index
40 all docs	40 docs citations	40 times ranked	2639 citing authors

#	Article	IF	Citations
1	Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome. Biostatistics, 2020, 21, 467-482.	1.5	6
2	Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Research, 2020, 80, 354-360.	0.9	22
3	Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective. Cancer Research, 2020, 80, 347-353.	0.9	9
4	A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. Genome Research, 2020, 30, 1170-1180.	5.5	4
5	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	2.5	7
6	Bayesian Semiparametric Estimation of Cancer-Specific Age-at-Onset Penetrance With Application to Li-Fraumeni Syndrome. Journal of the American Statistical Association, 2019, 114, 541-552.	3.1	8
7	Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Familial Cancer, 2018, 17, 287-294.	1.9	38
8	Longâ€term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report. Cancer, 2018, 124, 617-625.	4.1	14
9	Estimating TP53 Mutation Carrier Probability in Families with Liâ€“Fraumeni Syndrome Using LFSPRO. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 837-844.	2.5	14
10	Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	66
11	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	7.0	358
12	Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions. Clinical Cancer Research, 2017, 23, e14-e22.	7.0	80
13	Liâ€“Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. Trends in Pharmacological Sciences, 2017, 38, 908-927.	8.7	35
14	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
15	The cancer predisposition revolution. Science, 2016, 352, 1052-1053.	12.6	14
16	Characterization of Genomic Alterations in Radiation-Associated Breast Cancer among Childhood Cancer Survivors, Using Comparative Genomic Hybridization (CGH) Arrays. PLoS ONE, 2015, 10, e0116078.	2.5	10
17	Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Human Genetics, 2011, 130, 789-794.	3.8	10
18	Effects of measured susceptibility genes on cancer risk in family studies. Human Genetics, 2010, 127, 349-357.	3.8	11

#	Article	IF	Citations
19	Joint Effects of Germ-Line p53 Mutation and Sex on Cancer Risk in Li-Fraumeni Syndrome. Cancer Research, 2006, 66, 8287-8292.	0.9	86
20	Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Human Genetics, 2003, 113, 238-243.	3.8	94
21	The two-hit model for Wilms' tumor: Where are we 30 years later?. Genes Chromosomes and Cancer, 2003, 38, 294-299.	2.8	5
22	Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk. American Journal of Human Genetics, 2003, 72, 975-983.	6.2	225
23	Mutation in thePAX6 gene in twenty patients with aniridia. Human Mutation, 2000, 15, 332-339.	2.5	44
24	Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts. Oncogene, 1998, 17, 709-717.	5.9	53
25	A germline missense mutation R337C in exon 10 of the human p53 gene. Human Mutation, 1998, 11, S58-S61.	2.5	9
26	Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Human Genetics, 1998, 102, 681-686.	3.8	30
27	A splicing mutation in RB1 in low penetrance retinoblastoma. Human Genetics, 1997, 100, 557-563.	3.8	47
28	Three novel aniridia mutations in the human PAX6 gene. Human Mutation, 1995, 6, 44-49.	2.5	33
29	The Retinoblastoma Gene and its Significance. Annals of Medicine, 1994, 26, 177-184.	3.8	21
30	Genetic implications for long-term survivors of childhood cancer. Cancer, 1993, 71, 3435-3440.	4.1	13
31	Genetic mosaicism in normal tissues of Wilms' tumour patients. Nature Genetics, 1993, 3, 127-131.	21.4	79
32	Segregation analysis of 159 soft tissue sarcoma kindreds: Comparison of fixed and sequential sampling schemes. Genetic Epidemiology, 1992, 9, 291-304.	1.3	14
33	Genetic epidemiology of childhood brain tumors. Genetic Epidemiology, 1991, 8, 253-267.	1.3	69
34	Lack of linkage of familial Wilms' tumour to chromosomal band 11 p13. Nature, 1988, 336, 377-378.	27.8	224
35	The Genetic Implications of Long-Term Survival of Childhood Cancer: A Conceptual Framework. Journal of Pediatric Hematology/Oncology, 1987, 9, 99-103.	0.6	20
36	Familial aggregation of cancer in Laredo, Texas: A generally low-risk Mexican-American population. Genetic Epidemiology, 1986, 3, 121-143.	1.3	12

#	Article	IF	Citations
37	Aggregation of colon cancer in family data. Genetic Epidemiology, 1984, 1, 53-61.	1.3	14
38	A method to detect excess risk of disease in structured data: Cancer in relatives of retinoblastoma patients. Genetic Epidemiology, 1984, 1, 229-244.	1.3	41